The role of IGF-I and its binding proteins in the development of type 2 diabetes and cardiovascular disease
Autor: | Stephen B. Wheatcroft, Mark T. Kearney, Edward R. Duncan, Vivienne A. Ezzat |
---|---|
Rok vydání: | 2008 |
Předmět: |
business.industry
Endocrinology Diabetes and Metabolism Insulin medicine.medical_treatment MEDLINE Disease Type 2 diabetes Diabetic angiopathy medicine.disease Bioinformatics Insulin-Like Growth Factor Binding Protein 1 Endocrinology Insulin resistance Diabetes Mellitus Type 2 Risk Factors Diabetes mellitus Internal Medicine Humans Medicine Insulin Resistance Insulin-Like Growth Factor I Endothelial dysfunction business Diabetic Angiopathies |
Zdroj: | Diabetes, Obesity and Metabolism. 10:198-211 |
ISSN: | 1463-1326 1462-8902 |
DOI: | 10.1111/j.1463-1326.2007.00709.x |
Popis: | Patients with insulin resistance and type 2 diabetes have an excessive risk of cardiovascular disease (CVD); this increased risk is not fully explained by traditional risk factors such as hypertension and dyslipidaemias. There is now compelling evidence to suggest that abnormalities of insulin-like growth factor-I (IGF-I) and one of its binding proteins, insulin-like growth factor-binding protein-1 (IGFBP-1), occur in insulin-resistant states and may be significant factors in the pathophysiology of CVD. We reviewed articles and relevant bibliographies following a systematic search of MEDLINE for English language articles between 1966 and the present, using an initial search strategy combining the MeSH terms: IGF, diabetes and CVD. Our aim was first to review the role of IGF-I in vascular homeostasis and to explore the mechanisms by which it may exert its effects. We also present an overview of the physiology of the IGF-binding proteins, and finally, we sought to summarize the evidence to date describing the changes in the insulin/IGF-I/IGFBP-1 axis that occur in type 2 diabetes and CVD; in particular, we have focused on the potential vasculoprotective effects of both IGF-I and IGFBP-1. We conclude that this system represents an interesting and novel therapeutic target in the prevention of CVD in type 2 diabetes. |
Databáze: | OpenAIRE |
Externí odkaz: |